Clinical Trial Update: A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of JNJ-63723283, an Anti-Programmed Cell Death (PD)-1 Monoclonal Antibody, as Monotherapy or in Combination With Erdafitinib in Japanese Participants With Advanced Solid Cancers [Phase 1]

View source ↗

Summary

Phase 1 study evaluating safety, pharmacokinetics, pharmacodynamics, and immunogenicity of JNJ-63723283 as monotherapy or with Erdafitinib in Japanese patients …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• Erdafitinib (erdafitinib)
• JNJ-63723283

Snippet

Sponsor: Janssen Pharmaceutical K.K. | Conditions: Neoplasm | Phase 1 | Status: COMPLETED